Syn2bio (WAR:S2B) ROC (Joel Greenblatt) %: -900.61% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
9 GF Score
Price zł64.00
! 1 Warning Sign
View Full Analysis

What is Syn2bio ROC (Joel Greenblatt) %?

Syn2bio WAR:S2B -0.44% 9 ROC (Joel Greenblatt) % is -900.61% as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,322 Biotechnology companies, Syn2bio ranks worse than 65.73% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Syn2bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -900.61%.

The historical rank and industry rank for Syn2bio's ROC (Joel Greenblatt) % or its related term are showing as below:

WAR:S2B' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1044.33   Med: -930.12   Max: -900.61
Current: -900.61

During the past 3 years, Syn2bio's highest ROC (Joel Greenblatt) % was -900.61%. The lowest was -1044.33%. And the median was -930.12%.

WAR:S2B's ROC (Joel Greenblatt) % is ranked worse than
65.73% of 1322 companies
in the Biotechnology industry
Industry Median: -299.245 vs WAR:S2B: -900.61

Syn2bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Syn2bio  (WAR:S2B) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Syn2bio ROC (Joel Greenblatt) % Related Terms


Syn2bio ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Syn2bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio ROC (Joel Greenblatt) % Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
ROC (Joel Greenblatt) %
-1,044.33 -930.12 -900.61

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
ROC (Joel Greenblatt) % -1,044.33 -930.12 -900.61

WAR:S2B vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Syn2bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syn2bio ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syn2bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Syn2bio's ROC (Joel Greenblatt) % falls into.


WAR:S2B
9GF Score
Syn2bio SA WAR:S2B
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.388 + 0 + 0.117)
=-0.505

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + -8.8817841970013E-16) - (8.464 + 0 + 0.177)
=-8.641

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Syn2bio for the quarter that ended in Sep. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-28.923/( ( (2.936 + max(-0.505, 0)) + (3.487 + max(-8.641, 0)) )/ 2 )
=-28.923/( ( 2.936 + 3.487 )/ 2 )
=-28.923/3.2115
=-900.61 %

Note: The EBIT data used here is one times the annual (Sep. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -900.61% mean?
Syn2bio (WAR:S2B) has a ROC (Joel Greenblatt) % of -900.61% as of Sep. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Syn2bio and its competitors. According to the industry distribution chart, Syn2bio ranks #869 out of 1322 companies in the Biotechnology industry, placing it in the top 65.7%.
Is Syn2bio's ROC (Joel Greenblatt) % too high?
Syn2bio's current ROC (Joel Greenblatt) % is -900.61%. Based on the distribution chart, Syn2bio ranks #869 out of 1322 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn2bio ranks #869 out of 1322 companies for ROC (Joel Greenblatt) %. This places Syn2bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Syn2bio and its competitors. Syn2bio's current ROC (Joel Greenblatt) % is -900.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current ROC (Joel Greenblatt) % of -900.61%. The current ROC (Joel Greenblatt) % is -900.61%. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current ROC (Joel Greenblatt) % is -900.61% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score

Get the complete analysis for WAR:S2B

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł64.00
Price